Compare TGTX & TRNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TGTX | TRNO |
|---|---|---|
| Founded | 1993 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.0B |
| IPO Year | 1995 | 2010 |
| Metric | TGTX | TRNO |
|---|---|---|
| Price | $30.74 | $62.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 12 |
| Target Price | $51.60 | ★ $65.58 |
| AVG Volume (30 Days) | ★ 2.4M | 617.8K |
| Earning Date | 03-02-2026 | 02-04-2026 |
| Dividend Yield | N/A | ★ 3.32% |
| EPS Growth | N/A | ★ 75.67 |
| EPS | 2.78 | ★ 3.15 |
| Revenue | ★ $531,898,000.00 | $442,611,000.00 |
| Revenue This Year | $87.88 | $23.60 |
| Revenue Next Year | $47.78 | $7.96 |
| P/E Ratio | ★ $11.01 | $19.92 |
| Revenue Growth | ★ 100.88 | 21.13 |
| 52 Week Low | $25.28 | $48.18 |
| 52 Week High | $46.48 | $69.20 |
| Indicator | TGTX | TRNO |
|---|---|---|
| Relative Strength Index (RSI) | 53.06 | 67.22 |
| Support Level | $26.89 | $58.77 |
| Resistance Level | $33.24 | $60.45 |
| Average True Range (ATR) | 1.56 | 1.17 |
| MACD | 0.14 | 0.33 |
| Stochastic Oscillator | 60.55 | 93.72 |
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
Terreno Realty Corp is a real estate investment trust engaged in acquiring, owning, and operating industrial real estate in six coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. The company invests in several types of industrial real estate, including warehouse/distribution, flex (including light industrial and research and development), transshipment, and improved land.